PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1991 June; 84(6): 354–358.
PMCID: PMC1293284

Drug treatment of chronic venous insufficiency and venous ulceration: a review.

Abstract

Treatment of venous insufficiency and venous ulceration has for many years relied on established principles of compression and limb elevation. Drug treatment has been of little benefit. In recent years, a better understanding of the pathological mechanisms underlying skin damage in venous disease has allowed more rational pharmacotherapeutic approaches to be made. This review examines these, with special reference to current theories of the cause of venous ulceration.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Cornwall JV, Doré CJ, Lewis JD. Leg ulcers: epidemiology and aetiology. Br J Surg. 1986 Sep;73(9):693–696. [PubMed]
  • Callam MJ, Ruckley CV, Harper DR, Dale JJ. Chronic ulceration of the leg: extent of the problem and provision of care. Br Med J (Clin Res Ed) 1985 Jun 22;290(6485):1855–1856. [PMC free article] [PubMed]
  • Dale JJ, Callam MJ, Ruckley CV, Harper DR, Berrey PN. Chronic ulcers of the leg: a study of prevalence in a Scottish community. Health Bull (Edinb) 1983 Nov;41(6):310–314. [PubMed]
  • Bobek K, Cajzl L, Cepelak V, Slaisova V, Opatzny K, Barcal R. Etude de la fréquence des maladies phlébologiques et de l'influence de quelques facteurs étiologiques. Phlebologie. 1966 Jul-Sep;19(3):217–230. [PubMed]
  • Coon WW, Willis PW, 3rd, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation. 1973 Oct;48(4):839–846. [PubMed]
  • Baker PG, Haig G. Metronidazole in the treatment of chronic pressure sores and ulcers. A comparison with standard treatment in general practice. Practitioner. 1981 Apr;225(1354):569–573. [PubMed]
  • Jones PH, Willis AT, Ferguson IR. Treatment of anaerobically infected pressure sores with topical metronidazole. Lancet. 1978 Jan 28;1(8057):213–214. [PubMed]
  • Greaves MW, Skillen AW. Effects of long-continued ingestion of zinc sulphate in patients with venous leg ulceration. Lancet. 1970 Oct 31;2(7679):889–891. [PubMed]
  • Hallbök T, Lanner E. Serum-zinc and healing of venous leg ulcers. Lancet. 1972 Oct 14;2(7781):780–782. [PubMed]
  • Greaves MW, Ive FA. Double-blind trial of zinc sulphate in the treatment of chronic venous leg ulceration. Br J Dermatol. 1972 Dec;87(6):632–634. [PubMed]
  • Myers MB, Cherry G. Zinc and the healing of chronic leg ulcers. Am J Surg. 1970 Jul;120(1):77–81. [PubMed]
  • Phillips A, Davidson M, Greaves MW. Venous leg ulceration: evaluation of zinc treatment, serum zinc and rate of healing. Clin Exp Dermatol. 1977 Dec;2(4):395–399. [PubMed]
  • Schraibman IG, Stratton FJ. Nutritional status of patients with leg ulcers. J R Soc Med. 1985 Jan;78(1):39–42. [PMC free article] [PubMed]
  • Myers MB, Rightor M, Cherry G. Relationship between edema and the healing rate of stasis ulcers of the leg. Am J Surg. 1972 Nov;124(5):666–668. [PubMed]
  • Balmer A, Limoni C. Klinische, plazebokontrollierte Doppelblindprüfung von Venoruton bei der Behandlung der chronisch-venösen Insuffizienz. Die Bedeutung der Patientenauswahl. Vasa. 1980;9(1):76–82. [PubMed]
  • Pulvertaft TB. General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK. Vasa. 1983;12(4):373–376. [PubMed]
  • Bergqvist D, Hallbök T, Lindblad B, Lindhagen A. A double-blind trial of O-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency. Vasa. 1981;10(3):253–260. [PubMed]
  • Pulvertaft TB. Paroven in the treatment of chronic venous insufficiency. Practitioner. 1979 Dec;223(1338):838–841. [PubMed]
  • Browse NL, Burnand KG. The cause of venous ulceration. Lancet. 1982 Jul 31;2(8292):243–245. [PubMed]
  • Browse NL, Gray L, Jarrett PE, Morland M. Blood and vein-wall fibrinolytic activity in health and vascular disease. Br Med J. 1977 Feb 19;1(6059):478–481. [PMC free article] [PubMed]
  • Leach RD. Venous ulceration, fibrinogen and fibrinolysis. Ann R Coll Surg Engl. 1984 Jul;66(4):258–263. [PMC free article] [PubMed]
  • Wolfe JH, Morland M, Browse NL. The fibrinolytic activity of varicose veins. Br J Surg. 1979 Mar;66(3):185–187. [PubMed]
  • Browse NL, Jarrett PE, Morland M, Burnand K. Treatment of liposclerosis of the leg by fibrinolytic enhancement: a preliminary report. Br Med J. 1977 Aug 13;2(6084):434–435. [PMC free article] [PubMed]
  • Burnand K, Clemenson G, Morland M, Jarrett PE, Browse NL. Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression. Br Med J. 1980 Jan 5;280(6206):7–11. [PMC free article] [PubMed]
  • Dodd HJ, Gaylarde PM, Sarkany I. Skin oxygen tension in venous insufficiency of the lower leg. J R Soc Med. 1985 May;78(5):373–376. [PMC free article] [PubMed]
  • Aetiology of venous ulceration. Br J Surg. 1990 Sep;77(9):1071–1072. [PubMed]
  • Coleridge Smith PD, Thomas P, Scurr JH, Dormandy JA. Causes of venous ulceration: a new hypothesis. Br Med J (Clin Res Ed) 1988 Jun 18;296(6638):1726–1727. [PMC free article] [PubMed]
  • Sinzinger H, Virgolini I, Fitscha P. Pathomechanisms of atherosclerosis beneficially affected by prostaglandin E1 (PGE1)--an update. Vasa Suppl. 1989;28:6–13. [PubMed]
  • Beitner H, Hammar H, Olsson AG, Thyresson N. Prostaglandin E1 treatment of leg ulcers caused by venous or arterial incompetence. Acta Derm Venereol. 1980;60(5):425–430. [PubMed]
  • Rudofsky G. Intravenous prostaglandin E1 in the treatment of venous ulcers--a double-blind, placebo-controlled trial. Vasa Suppl. 1989;28:39–43. [PubMed]
  • Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology. 1984 Jul;35(7):396–406. [PubMed]
  • Sullivan GW, Carper HT, Novick WJ, Jr, Mandell GL. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun. 1988 Jul;56(7):1722–1729. [PMC free article] [PubMed]
  • Angelides NS, Weil von der Ahe CA. Effect of oral pentoxifylline therapy on venous lower extremity ulcers due to deep venous incompetence. Angiology. 1989 Aug;40(8):752–763. [PubMed]
  • Colgan MP, Dormandy JA, Jones PW, Schraibman IG, Shanik DG, Young RA. Oxpentifylline treatment of venous ulcers of the leg. BMJ. 1990 Apr 14;300(6730):972–975. [PMC free article] [PubMed]
  • Müller B, Krais T, Stürzebecher S, Witt W, Schillinger E, Baldus B. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease. Biomed Biochim Acta. 1988;47(10-11):S40–S44. [PubMed]
  • Musiał J, Wilczyńska M, Sładek K, Cierniewski CS, Nizankowski R, Szczeklik A. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins. 1986 Jan;31(1):61–70. [PubMed]
  • Müller B, Schmidtke M, Witt W. Adherence of leucocytes to electrically damaged venules in vivo. Effects of iloprost, PGE1, indomethacin, forskolin, BW 755 C, sulotroban, hirudin, and thrombocytopenia. Eicosanoids. 1988;1(1):13–17. [PubMed]
  • De Felice M, Gallo P, Masotti G. Current therapy of peripheral obstructive arterial disease. The non-surgical approach. Angiology. 1990 Jan;41(1):1–11. [PubMed]
  • Van Acker K, Rillaerts E, De Leeuw I. The influence of buflomedil on blood viscosity parameters in insulin-dependent diabetic patients: a preliminary study. Biomed Pharmacother. 1989;43(3):219–222. [PubMed]
  • Daum PS, Bowers WD, Jr, Tejada J, Morehouse D, Hamlet MP. An evaluation of the ability of the peripheral vasodilator buflomedil to improve vascular patency after acute frostbite. Cryobiology. 1989 Feb;26(1):85–92. [PubMed]
  • Mannarino E, Pasqualini L, Maragoni G, Orlandi U. Effect of buflomedil chlorhydrate on local oxygen delivery in peripheral vascular disease. Angiology. 1989 Jun;40(6):559–562. [PubMed]
  • Lavaud P, Mathieu J, Bienvenu P, Braquet M, Gerasimo P, Kergonou JF, Ducousso R. Modulation of leucocyte activation in the early phase of the rabbit burn injury. Burns Incl Therm Inj. 1988 Feb;14(1):15–20. [PubMed]
  • Pincemail J, Dupuis M, Nasr C, Hans P, Haag-Berrurier M, Anton R, Deby C. Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia. 1989 Aug 15;45(8):708–712. [PubMed]
  • Otamiri T, Tagesson C. Ginkgo biloba extract prevents mucosal damage associated with small-intestinal ischaemia. Scand J Gastroenterol. 1989 Aug;24(6):666–670. [PubMed]
  • Kurihara K, Wardlaw AJ, Moqbel R, Kay AB. Inhibition of platelet-activating factor (PAF)-induced chemotaxis and PAF binding to human eosinophils and neutrophils by the specific ginkgolide-derived PAF antagonist, BN 52021. J Allergy Clin Immunol. 1989 Jan;83(1):83–90. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press